S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
Log in
NASDAQ:BCAB

BioAtla Stock Forecast, Price & News

$45.38
-1.14 (-2.45 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$44.97
Now: $45.38
$48.15
50-Day Range N/A
52-Week Range
$27.15
Now: $45.38
$49.49
Volume122,260 shs
Average Volume257,976 shs
Market Capitalization$1.46 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.

MarketRank

Overall MarketRank

1.63 out of 5 stars

Analyst Opinion: 1.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BCAB
CUSIPN/A
CIKN/A
Phone858 558 0708
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$1.46 billion
Next Earnings DateN/A
OptionableNot Optionable
$45.38
-1.14 (-2.45 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BCAB News and Ratings via Email

Sign-up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioAtla (NASDAQ:BCAB) Frequently Asked Questions

Is BioAtla a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BioAtla stock.
View analyst ratings for BioAtla
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than BioAtla?

Wall Street analysts have given BioAtla a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioAtla wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for BCAB?

4 Wall Street analysts have issued 12-month target prices for BioAtla's shares. Their forecasts range from $45.00 to $51.00. On average, they anticipate BioAtla's share price to reach $48.00 in the next twelve months. This suggests a possible upside of 5.8% from the stock's current price.
View analysts' price targets for BioAtla
or view Wall Street analyst' top-rated stocks.

Who are some of BioAtla's key competitors?

Who are BioAtla's key executives?

BioAtla's management team includes the following people:
  • Dr. Jay M. Short, Co-Founder, CEO & Chairman (Age 62)
  • Mr. Scott Andrew Smith, Pres & Director (Age 58)
  • Ms. Carolyn Anderson Short, Co-Founder, Assistant Sec. and Chief of Intellectual Property & Strategy (Age 56)
  • Mr. Richard A. Waldron, Chief Financial Officer (Age 66)
  • Lisa M. Pelton, Accounting Mang.
  • Ms. Susie Melody, VP of HR
  • Dr. Eric L. Sievers, Chief Medical Officer (Age 56)
  • Mr. Philippe Martin, Head of Pharmaceutical Operations & Devel. Team Leader (Age 45)
  • Mr. Christian Vasquez, VP of Fin., Corp. Controller & Sec. (Age 44)

When did BioAtla IPO?

(BCAB) raised $150 million in an initial public offering on Wednesday, December 16th 2020. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG served as the underwriters for the IPO.

What is BioAtla's stock symbol?

BioAtla trades on the NASDAQ under the ticker symbol "BCAB."

When does the company's quiet period expire?

BioAtla's quiet period expires on Monday, January 25th. BioAtla had issued 10,500,000 shares in its public offering on December 16th. The total size of the offering was $189,000,000 based on an initial share price of $18.00. During the company's quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of BioAtla?

Shares of BCAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioAtla's stock price today?

One share of BCAB stock can currently be purchased for approximately $45.38.

How big of a company is BioAtla?

BioAtla has a market capitalization of $1.46 billion.

What is BioAtla's official website?

The official website for BioAtla is www.bioatla.com.

How can I contact BioAtla?

The company can be reached via phone at 858 558 0708.

This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.